There’s plenty of hope that the COVID-19 disease will soon become as dangerous as a common cold. The UK government is proud to announce the discovery of two new life-saving treatments for those infected with COVID-19.
Tocilizumab and sarilumab, the two anti-inflammatory drugs that are usually used for arthritis, may not mean too much for you if you’re not among the COVID-19 patients. But for those affected by the pandemic disease and who live in the UK, the drugs will be life-saving.
The drugs reduce the death risk by 24%
Tocilizumab and sarilumab will save a lot of lives among those who suffer from the SARS-CoV-2 virus, according to the news brought by Business Insider. Also, the patients who will receive the two drugs will spend ten days less in the hospital. The conclusion comes after a government-funded study known as the REMAP-CAP trial, although it wasn’t published or peer-reviewed.
Professor Jonathan Van-Tam, who’s the UK’s deputy chief medical officer, declared:
The data shows that tocilizumab, and likely sarilumab, speed up and improve the odds of recovery in intensive care, which is crucial for helping to relieve pressure on intensive care and hospitals and saving lives.
NHS clinicians are expected to treat patients in intensive care units with the tocilizumab and sarilumab drugs Friday, January 8.
Adam Jacobs, the director of Biostatistics at Premier Research, declared:
The bottom line is that although I have a few concerns about the details of this study, if I were in intensive care with COVID, I would definitely want my doctors to give me tocilizumab now that I’ve read this paper.
The world sure needs new ways of fighting the pandemic disease, as the current overall situation looks pretty bad: over 89 million infections and more than 1.9 million deaths worldwide.